A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-08

Study Completion Date

2025-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Designed to Evaluate Tear Production

NCT06544707

Dry Eye Disease

COMPLETED PHASE3

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644

Dry Eye Disease

COMPLETED PHASE3

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290

Dry Eye Disease

COMPLETED PHASE3

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111

Dry Eye Disease

COMPLETED PHASE3

Study Evaluating Techniques for Measuring Tear Production

NCT05497479

Dry Eye Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Qualified subjects will enter a 14-day run-in period, followed by a 13-week randomized treatment period, for a total individual duration of participation of approximately 15 weeks. During the run-in period, subjects will administer Artificial Tears (REFRESH® Classic) as one drop in each eye twice daily.

This is a Phase 3b study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.003% AR-15512

One drop in each eye twice daily for 90 days (treatment period)

Group Type EXPERIMENTAL

0.003% AR-15512

Intervention Type DRUG

Ophthalmic solution administered via topical ocular instillation

Artificial Tears

One drop in each eye twice daily for 90 days (treatment period)

Group Type ACTIVE_COMPARATOR

Artificial Tears

Intervention Type OTHER

Commercially available, preservative-free lubricant eye drops

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

0.003% AR-15512

Ophthalmic solution administered via topical ocular instillation

Intervention Type DRUG

Artificial Tears

Commercially available, preservative-free lubricant eye drops

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

REFRESH® Classic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a previous history of DED, clinician diagnosed or patient reported, within the previous 6 months prior to the Screening visit.
* Have used artificial tears for DED symptoms within 2 months prior to the Screening visit.
* Corrected visual acuity equal to or better than logarithm Minimum angle of reflection (logMar) +0.7 (Snellen equivalent equal to or better than 20/100), as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at both the Screening and Baseline visits.
* Good general and ocular health, as determined by the investigator using medical history, ophthalmic examination and history.

Exclusion Criteria

* History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety.
* Current evidence of other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation.
* History of ocular surgery within 1 year prior to the Screening visit; history of corneal transplant in one or both eyes.
* Use of contact lenses in either eye within 7 days prior to the Screening visit or planned use during the study.
* Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Screening visit or any planned use during the study.
* Use of lid heating therapy or Meibomian gland probing/therapeutic expression within 1 year prior to the Screening visit or anticipated during the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No